UpSurgeOn Raises €5M ($5.8M) for Neurosurgical Training
UpSurgeOn, a Milan-based developer of hyper-realistic, cadaver-free surgical simulation technologies, has raised €5M ($5.8M) in funding led by CDP Venture Capital. The company provides physical models, AR/VR apps, and AI tools for neurosurgery, spine surgery, and microsurgical training. These products, including the Cranial Series and Spine Series, enhance learning curves and reduce training costs for surgical trainees and MedTech firms. The new capital will fund global expansion, R&D on psychomotor skill augmentation, and development for new specialties like orthopedics and ENT.
Simulation Funding Hits €10M+ Wave
The round follows a €3M raise in 2022 from Guala Dispensing, bringing total institutional funding over €8M per FinSMEs. It coincides with Oxford Medical Simulation securing €5.78M for VR training expansion in March 2026. UpSurgeOn's hybrid physical-digital approach stands out against pure VR plays like Osso VR, which raised $109M total per Crunchbase. This signals investor conviction in simulation tech amid surgeon training shortages.
Cadaver Costs Fuel Simulator Shift
Surgical training faces cadaver shortages and high costs, limiting repeatable practice especially in low- and middle-income countries (LMICs). UpSurgeOn's solutions enable cadaver-free training, with products adopted by 500+ scientific institutions and 300+ MedTech companies across 110+ countries per company site. Recent traction shows reach in 130 countries, training 5,000+ professionals in 2025, and tripled shipments per company posts. Studies validate 80% realism ratings and 86% faster performance in LMICs.
Hybrid Sims Outpace Digital-Only
UpSurgeOn combines lifelike physical models with AR overlays and apps for measurable skill feedback, differentiating from FundamentalVR's ($25M+) haptic VR or ImmersiveTouch's ($7.2M) planning tools per market research. Their Spine Deformity platform, launched in 2026, offers biomechanical responses for multiple pathologies. Compatibility with robotic systems yields 40% greater accuracy and 30% fewer errors [per recent activity].
As Federico Nicolosi, Founder & CEO, noted:
"We are extremely proud and motivated by this important round and honored to collaborate with highly visionary partners… ultimate goal of our work is the patient’s well-being."
Italian Capital Backs Global Scale
CDP Venture Capital's Evoluzione Fund led, joined by SIMEST, Deep Blue Ventures, Azimut Libera Impresa SGR, and FBH S.p.A. per StartupRise. This mix of public and private Italian backers validates UpSurgeOn's mission to democratize surgical excellence. Mario Scuderi of CDP highlighted the team's potential to redefine standards and improve patient safety.
$457M Market Grows to $1.14B
The surgical simulation market stood at $457M in 2024, projected to reach $1.14B by 2030 at 16.4% CAGR per Grand View Research. Another estimate pegs it at $587M with 15% CAGR per MarketsandMarkets. Trends like AI personalization and VR/AR hybrids drive growth, favoring UpSurgeOn's neurosurgery focus over broader competitors like VirtaMed.
Neurosurgeon Founders Drive Realism
Founders Federico Nicolosi (CEO, practicing neurosurgeon, Adj. Professor) and Giannantonio Spena (Co-Founder, Chief of Neurosurgery) bring direct OR experience per LinkedIn. Nicolosi treated patients at Humanitas Research Hospital; Spena led departments at major Italian hospitals. Their expertise ensures hyper-realistic simulations, backed by 9 international patents.
Orthopedics Entry Accelerates Growth
Funds target U.S. expansion via partner Inovus Medical, orthopedics and ENT platforms, and AI psychomotor enhancements per FinSMEs. Recent Spine Deformity launch and global events in 130 countries position UpSurgeOn for scaled adoption.